• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacology, Biochemistry and Behavior >Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake.
【24h】

Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake.

机译：行为饱腹感序列（BSS）用于诊断药物对食物摄入的作用。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The Behavioral Satiety Sequence (BSS) is the name given to the orderly transitions of eating, activity grooming and resting measured during the postingestive period. Because the BSS is considered to reflect the operations of natural physiological processes underlying satiety, the sequence can be used to discriminate between different drugs (and other manipulations) that reduce food intake via these natural physiological mechanisms or those that do so by interference. The BSS is only produced by the presence of a caloric load in the gut, and the preabsorptive satiety factors (such as CCK) the caloric load triggers. The BSS is most accurately defined by continuous observation rather than time or event sampling techniques [Partial Time Sampling (PTS) or Momentary Time Sampling (MTS)]. Continuous observation also allows the true duration and true frequency of each behavior to be analyzed. Continuous observation can be used to determine if the profiles associated with the reduction in food intake is caused by nausea, sedation, hyperactivity, or altered palatability of food. At the present time is it possible to identify a number of drugs whose suppression of food intake is associated with the disruption or preservation of the BSS. Drugs that increase synaptic 5-HT activity such d-fenfluramine, fluoxetine. and sibutramine all preserve the BSS and advance the onset of resting. The 5-HT1b/2c agonists mCPP and TFMPP and the 5-HT1b agonist CP-94,253 produce similar effects. However, the 5-HT2 agonist DOI and the 5-HT1a/1b agonist RU-24969 disrupt the BSS by inducing hyperactivity as does amphetamine. The 5-HT2 agonist MK-212 disrupts the BSS by inducing sedation. Selective dopamine agonists, at low doses, such as SKF-38393 (DA1) and LY-171555 (DA2) also preserve the BSS. However, detailed behavioral analysis of the effects of many recently discovered putative satiety factors remains to be carried out.
机译：行为饱腹感序列（BSS）是在发情期测量的饮食，活动修饰和休息的有序转变的名称。由于BSS被认为反映了饱腹感背后的自然生理过程的操作，因此该序列可用于区分通过这些自然生理机制或通过干扰而减少食物摄入量的不同药物（和其他操作）。 BSS仅由肠道中存在热量负荷以及热量负荷触发的吸收前饱食因子（例如CCK）产生。 BSS是通过连续观察而非时间或事件采样技术[部分时间采样（PTS）或瞬时时间采样（MTS）]来最准确地定义的。连续观察还可以分析每种行为的真实持续时间和真实频率。连续观察可用于确定与食物摄入减少相关的特征是否是由于恶心，镇静，机能亢进或食物适口性改变引起的。目前，有可能识别出其抑制食物摄入与BSS的破坏或保存有关的许多药物。增强突触5-HT活性的药物，例如d-芬氟拉明，氟西汀。西布曲明和西布曲明都能保护BSS并促进静息发作。 5-HT1b / 2c激动剂mCPP和TFMPP和5-HT1b激动剂CP-94,253产生相似的效果。但是，5-HT2激动剂DOI和5-HT1a / 1b激动剂RU-24969与苯丙胺一样，通过诱导过度活跃来破坏BSS。 5-HT2激动剂MK-212通过诱导镇静作用破坏BSS。低剂量的选择性多巴胺激动剂，例如SKF-38393（DA1）和LY-171555（DA2），也可以保护BSS。但是，对许多最近发现的饱足感因素的影响进行详细的行为分析仍需进行。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号